AMPAC re-opens 50,000 gallon API facility in Virginia

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/PBFloyd)
(Image: Getty/PBFloyd)

Related tags: API, facility, Investment, Ampac, Manufacturing, analytical

After being acquired by SK Holdings, AMPAC re-opens its API manufacturing facility in Virginia as part of a growing investment in its US capabilities.

AMPAC Fine Chemicals (AFC) re-opened its manufacturing operations at its active pharmaceutical ingredient (API) facility in Petersburg, US, after the site saw infrastructure refurbishment.

According to AFC, the pharmaceutical ingredients manufactured at the plant will be for pharmaceutical companies across the US and will be used in the production of treatments for central nervous system deficiencies, cancer, and epilepsy.

The expansion of the US-based company’s operations comes shortly after it was acquired as a portfolio company by SK holdings, an investment holding company of the South Korean SK Group.

The Petersburg site encompasses around 200 acres of the city’s industrial complex and has a 50,000-gallon capacity. With the re-opening, 100 jobs are expected to generate over the next few years.

AFC president and CEO, Aslam Malik, said in a statement that the re-opening of the plant demonstrates the company’s interest in employing more local residents, its growing investment in the US, and to create opportunities to develop community partnerships.

The company has operations in La Porte, Texas, Petersburg, Virginia, and both Rancho Cordova and El Dorado Hills, California. Its global offerings extend beyond technology platforms for API production including, continuous processes and industrial scale chromatographic separation, highly potent compound manufacturing, and analytical services.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more